X4 Pharmaceuticals regains Nasdaq bid price compliance; deficiency notice closed

X4 Pharmaceuticals, Inc

Received Nasdaq deficiency notice on Nov 13, 2023 for bid price below $1.00 for 30 consecutive trading days.
On April 5, 2024, Nasdaq confirmed compliance with Bid Price Rule; matter now closed.
Common stock (XFOR) remains listed on The Nasdaq Stock Market.

item 8.01

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-24-015059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.